GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (FRA:3O61) » Definitions » Balance Sheet Cash And Cash Equivalents

Cascadian Therapeutics (FRA:3O61) Balance Sheet Cash And Cash Equivalents


View and export this data going back to . Start your Free Trial

What is Cascadian Therapeutics Balance Sheet Cash And Cash Equivalents?

Please go to this page to see Cash And Cash Equivalents for non-financial companies.


Cascadian Therapeutics (FRA:3O61) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.